Differential Outcomes for Long Term ex vivo Lung Perfusion in a Porcine Model - With or without Red Cells?

2015 ◽  
Vol 63 (S 01) ◽  
Author(s):  
W. Sommer ◽  
M. Avsar ◽  
J. Salman ◽  
C. Kühn ◽  
I. Tudorache ◽  
...  
Keyword(s):  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Red Cells ◽  
Ex Vivo Lung Perfusion ◽  
Differential Outcomes

Differential Outcomes for Long Term Ex Vivo Lung Perfusion in a Porcine Model - With or Without Red Cells?

2015 ◽  
Vol 34 (4) ◽  
pp. S282
Author(s):  
W. Sommer ◽  
J. Salman ◽  
M. Avsar ◽  
T. Siemeni ◽  
K. Jansson ◽  
...  
Keyword(s):  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Red Cells ◽  
Ex Vivo Lung Perfusion ◽  
Differential Outcomes

Differential Outcomes for Long Term Ex Vivo Lung Perfusion in a Porcine Model -With or Without Red Cells?

2014 ◽  
Vol 98 ◽  
pp. 340
Author(s):  
W. Sommer ◽  
M. Avsar ◽  
J. Salman ◽  
K. Jansson ◽  
C. Kuehn ◽  
...  
Keyword(s):  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Red Cells ◽  
Ex Vivo Lung Perfusion ◽  
Differential Outcomes

Effects of Short and Long Term Cold Static Preservation Followed by Normothermic Ex Vivo Lung Perfusion in a Porcine Model

2018 ◽  
Vol 37 (4) ◽  
pp. S224
Author(s):  
C. Olbertz ◽  
N. Pizanis ◽  
H. Bäumker ◽  
U. Rauen ◽  
I. Nolte ◽  
...  
Keyword(s):  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Ex Vivo Lung Perfusion ◽  
Short And Long Term

Long Term Outcomes of Ex Vivo Lung Perfusion: A Single Center 10 Year Experience

2018 ◽  
Vol 37 (4) ◽  
pp. S148-S149
Author(s):  
C. Divithotawela ◽  
M. Cypel ◽  
S. Azad ◽  
L. Singer ◽  
M. Binnie ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Lung Perfusion ◽  
Single Center ◽  
Long Term Outcomes ◽  
Ex Vivo Lung Perfusion

Cost Effectiveness of Ex Vivo Lung Perfusion Warrants Analysis of Long Term Recipient Outcome and Donor Organ Utilization Rate

2015 ◽  
Vol 34 (4) ◽  
pp. S174 ◽  
Author(s):  
P.M. Hopkins ◽  
D. Chambers ◽  
I. Smith ◽  
R. Naidoo ◽  
D. Wall ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Utilization Rate ◽  
Donor Organ ◽  
Ex Vivo Lung Perfusion

Comparison between cellular and acellular perfusates for ex vivo lung perfusion in a porcine model

2015 ◽  
Vol 34 (7) ◽  
pp. 978-987 ◽  
Author(s):  
Marius Roman ◽  
Olivera Gjorgjimajkoska ◽  
Desley Neil ◽  
Sukumaran Nair ◽  
Simon Colah ◽  
...  
Keyword(s):  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Ex Vivo Lung Perfusion

scholarly journals Custodiol-MP for ex vivo lung perfusion – A comparison in a porcine model of donation after circulatory determination of death

2021 ◽  
pp. 039139882199066
Author(s):  
Katharina Kalka ◽  
Zoe Keldenich ◽  
Henning Carstens ◽  
Björn Walter ◽  
Ursula Rauen ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Functional Outcomes ◽  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Determination Of Death ◽  
Ex Vivo Lung Perfusion ◽  
Lactate Dehydrogenase Activity ◽  
Lactate Levels

Introduction: Ex vivo lung perfusion (EVLP) is an established technique to evaluate and eventually recondition lungs prior to transplantation. Custodiol-MP (C-MP) solution is a new solution, designed for clinical machine perfusion, that has been used for kidneys. The aim of this study was to compare the effects of EVLP with Custodiol-MP on lung functional outcomes to the gold standard of EVLP with Steen Solution™. Material and Methods: In a porcine EVLP model of DCDD (Donation after Circulatory Determination of Death), lungs were perfused with Steen Solution™ (SS, n = 7) or Custodiol-MP solution supplemented with 55 g/l albumin (C-MP, n = 8). Lungs were stored cold for 4 h in low potassium dextran solution and subsequently perfused ex vivo for 4 h. During EVLP pulmonary gas exchange, activities of lactate dehydrogenase (LDH) and alkaline phosphatase (AP) as well as levels of lactate in the perfusate were recorded hourly. Results: Oxygenation capacity differed significantly between groups (averaged over 4 h: SS 274 ± 178 mmHg; C-MP 284 ± 151 mmHg p = 0.025). Lactate dehydrogenase activities and lactate concentrations were significantly lower in Custodiol-MP perfused lungs. In a porcine model of DCDD with 4 h of EVLP the use of modified Custodiol-MP as perfusion solution was feasible. The use of C-MP showed at least comparable lung functional outcomes to the use of Steen SolutionTM. Furthermore C-MP perfusion resulted in significantly lower lactate dehydrogenase activity and lactate levels in the perfusate and higher oxygenation capacity.

scholarly journals Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion

JAMA Surgery ◽  
2019 ◽  
Vol 154 (12) ◽  
pp. 1143 ◽  
Author(s):  
Chandima Divithotawela ◽  
Marcelo Cypel ◽  
Tereza Martinu ◽  
Lianne G. Singer ◽  
Matthew Binnie ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Long Term Outcomes ◽  
Ex Vivo Lung Perfusion

scholarly journals Porcine Model of Donation after Cardiac Death (DCD) and Evaluation of Pulmonary Function Using Ex-vivo Lung Perfusion (EVLP)

2019 ◽  
Vol 9 (1) ◽  
pp. 40-48
Author(s):  
Malek Dhane
Keyword(s):  
Weight Gain ◽  
Cardiac Death ◽  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Warm Ischemia ◽  
The Body ◽  
Cold Ischemia ◽  
Ex Vivo Lung Perfusion ◽  
Ischemic Time

Objective The limiting factor when using lungs from donors after cardiac death (DCD) is the duration of warm ischemic time, which is linked to reperfusion edema. Within the context of lung shortages, and in order to avoid transplanting damaged lungs, ex-vivo lung perfusion (EVLP) has emerged as an innovative tool to preserve and recondition donor lungs. Using the EVLP technique in a porcine model, the purpose of this study is to determine the duration of warm ischemia that donor lungs can tolerate before they are viewed as non-viable for transplant. Methods This study is comprised of 5 groups (n=2-6/group).  Four groups endured different warm ischemic times, whilst the fifth group underwent cold ischemia. The lungs were subsequently perfused outside the body using the EVLP platform for four hours. Results 120 minutes of warm ischemia is more damaging for lungs than 120 minutes of cold ischemia, even after being reconditioned on the EVLP platform (50,4 ± 8,9% vs. 3,3 ± 3,4% of weight gain). This would signify that two hours of warm ischemia is incompatible with transplantation. However, 90 minutes and 60 minutes of warm ischemia seems to have less of an effect on pulmonary functions. Indeed, the lungs of both these groups had less than 14% of weight gain and maintained oxygenating capacities (PaO2/FiO2 of 514 ± 12 and 586 ± 0 mmHg respectively.) Conclusion Lungs having been submitted to less than 90 minutes of warm ischemia and evaluated with EVLP may be suitable candidates for transplantation.

scholarly journals MG53 as a Novel Therapeutic Protein to Treat Acute Lung Injury

2021 ◽  
Vol 186 (Supplement_1) ◽  
pp. 339-345
Author(s):  
Bryan A Whitson ◽  
Kristine Mulier ◽  
Haichang Li ◽  
Xinyu Zhou ◽  
Chuanxi Cai ◽  
...  
Keyword(s):  
Acute Lung Injury ◽  
Epithelial Cells ◽  
Lung Injury ◽  
Hemorrhagic Shock ◽  
Porcine Model ◽  
Ex Vivo ◽  
Lung Perfusion ◽  
Human Bronchial Epithelial Cells ◽  
Ex Vivo Lung Perfusion ◽  
Bronchial Epithelial

ABSTRACT Introduction Lung injury has several inciting etiologies ranging from trauma (contusion and hemorrhage) to ischemia reperfusion injury. Reflective of the injury, tissue and cellular injury increases proportionally with the injury stress and is an area of potential intervention to mitigate the injury. This study aims to evaluate the therapeutic benefits of recombinant human MG53 (rhMG53) protein in porcine models of acute lung injury (ALI). Materials and Methods We utilized live cell imaging to monitor the movement of MG53 in cultured human bronchial epithelial cells following mechanical injury. The in vivo efficacy of rhMG53 was evaluated in a porcine model of hemorrhagic shock/contusive lung injury. Varying doses of rhMG53 (0, 0.2, or 1 mg/kg) were administered intravenously to pigs after induction of hemorrhagic shock/contusive induced ALI. Ex vivo lung perfusion system enabled assessment of the isolated porcine lung after a warm ischemic induced injury with rhMG53 supplementation in the perfusate (1 mg/mL). Results MG53-mediated cell membrane repair is preserved in human bronchial epithelial cells. rhMG53 mitigates lung injury in the porcine model of combined hemorrhagic shock/contusive lung injury. Ex vivo lung perfusion administration of rhMG53 reduces warm ischemia-induced injury to the isolated porcine lung. Conclusions MG53 is an endogenous protein that circulates in the bloodstream. Therapeutic treatment with exogenous rhMG53 may be part of a strategy to restore (partially or completely) structural morphology and/or functional lung integrity. Systemic administration of rhMG53 constitutes a potential effective therapeutic means to combat ALI.

Sign in / Sign up

Export Citation Format

Share Document